Add like
Add dislike
Add to saved papers

Sub 4 minute superfast single-photon emission computed tomography/computed tomography as an add-on for problem-solving in planar bone scintigraphy: a time-saving solution for departments without whole-body single-photon emission computed tomography/computed tomography.

Whole-body bone scintigraphy remains widely used in nuclear medicine as it is a relatively inexpensive and quick test in which the whole body can be imaged with good sensitivity. However, one downside of the technique is its lack of specificity. The difficulty comes when there is a single 'hot spot' which usually requires further anatomical imaging to identify the cause and differentiate malignant from benign lesions. In this situation, hybrid imaging with single-photon emission computed tomography/computed tomography (SPECT/CT) can be a useful problem solver. The addition of SPECT/CT can however, be time-consuming, adding up to 15-20 min for every bed position required, a process that can tax the compliance of the patient and reduce the scanning capacity of the department. We report the successful implementation of a new superfast SPECT/CT protocol comprising a 1 s per view over 24 views point and shoot approach, reducing the SPECT scan time to less than 2 min and the whole SPECT/CT to under 4 min while still producing images that allow diagnostic certainty in previously equivocal lesions. This is faster than previously reported ultrafast SPECT/CT protocols. The utility of the technique is demonstrated in a pictorial review of four disparate causes of solitary bone lesions: fracture, metastasis, degenerative arthropathy and Paget's disease. This technique may prove a cost-effective problem-solving adjunct in nuclear medicine departments unable to yet offer whole-body SPECT/CT to every patient, without adding much burden to the department's gamma camera usage and patient throughput.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app